ABOUT TAURIGA SCIENCES INC.
DISCLAIMER — Forward-Looking Statements
Please visit the Company’s recently upgraded E-Commerce website, at: https://taurigum.com
The Company is firmly on track to generate record quarterly revenue (net revenue), for its 3 rd Fiscal Quarter 2022. The Company expects that net revenue generated for this quarter, when completed, will be substantially greater than any other previous quarter.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
NEW YORK, NY, Nov. 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has generated record weekly net E-Commerce revenue (“sales”), for the following period: Monday November 22, 2021 through Sunday November 28, 2021. The Company’s net E-Commerce sales, for this one-week period, have exceeded $22,000 for the first time. The Company is confident about its business prospects for the remainder of Calendar Year 2021 and beyond.
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
To continue, please click the box below to let us know you’re not a robot.
For inquiries related to this message please contact our support team and provide the reference ID below.